A detailed history of Oliver Lagore Vanvalin Investment Group transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Oliver Lagore Vanvalin Investment Group holds 500 shares of NUVB stock, worth $1,170. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Holding current value
$1,170
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$2.58 - $3.69 $1,290 - $1,845
500 New
500 $1,000

Others Institutions Holding NUVB

About Nuvation Bio Inc.


  • Ticker NUVB
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 217,244,000
  • Market Cap $508M
  • Description
  • Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...
More about NUVB
Track This Portfolio

Track Oliver Lagore Vanvalin Investment Group Portfolio

Follow Oliver Lagore Vanvalin Investment Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oliver Lagore Vanvalin Investment Group, based on Form 13F filings with the SEC.

News

Stay updated on Oliver Lagore Vanvalin Investment Group with notifications on news.